Table 2.
Results from logistic regression models
| Effectiveness | Tolerability | |||||
|---|---|---|---|---|---|---|
| OR | 95% CI | P value | OR | 95% CI | P value | |
| Baseline parameter | ||||||
| Satisfaction at baseline | 2.98 | 2.58 to 3.44 | <0.0001 | 2.40 | 2.03 to 2.83 | <0.0001 |
| Seropositivity | 1.36 | 1.17 to 1.57 | <0.0001 | 1.22 | 1.04 to 1.43 | 0.0129 |
| ≥1 bDMARD prior to enrolment | 0.78 | 0.66 to 0.92 | 0.0042 | 0.97 | 0.79 to 1.21 | 0.8134 |
| Depression | 0.64 | 0.51 to 0.80 | <0.0001 | 0.54 | 0.43 to 0.68 | <0.0001 |
| Fibromyalgia | 0.70 | 0.51 to 0.96 | 0.0257 | 0.79 | 0.56 to 1.10 | 0.1656 |
| Obesity (BMI ≥30 kg/m2, ref. <30 kg/m2) | 0.86 | 0.74 to 0.99 | 0.0377 | 0.93 | 0.78 to 1.11 | 0.4485 |
| Heart failure | 1.23 | 0.77 to 1.98 | 0.3884 | 0.92 | 0.58 to 1.45 | 0.7151 |
| Diabetes | 0.93 | 0.74 to 1.17 | 0.5468 | 0.87 | 0.70 to 1.08 | 0.2023 |
| Chronic kidney disease | 0.97 | 0.71 to 1.32 | 0.8467 | 1.05 | 0.71 to 1.55 | 0.8145 |
| Malignant neoplasm | 1.02 | 0.71 to1.45 | 0.9249 | 0.93 | 0.64 to 1.35 | 0.7041 |
| Degenerative spine disease | 0.93 | 0.76 to 1.12 | 0.4309 | 0.87 | 0.71 to 1.06 | 0.1611 |
| Osteoarthritis | 0.90 | 0.75 to 1.07 | 0.2416 | 0.94 | 0.78 to 1.13 | 0.4801 |
| Osteoporosis | 0.93 | 0.77 to 1.12 | 0.4491 | 0.98 | 0.79 to 1.22 | 0.8527 |
| Age at onset (10 years) | 1.04 | 0.98 to 1.10 | 0.1792 | 1.00 | 0.94 to 1.06 | 0.9362 |
| Female sex | 1.08 | 0.92 to 1.28 | 0.3344 | 1.12 | 0.93 to 1.36 | 0.2372 |
| Former smoking | 0.91 | 0.76 to 1.08 | 0.2702 | 0.96 | 0.79 to 1.16 | 0.6685 |
| Current smoking | 0.96 | 0.80 to 1.15 | 0.6586 | 0.99 | 0.83 to 1.19 | 0.9421 |
| No information on smoking | 1.12 | 0.77 to 1.62 | 0.5517 | 0.92 | 0.65 to 1.30 | 0.6398 |
| Parameter after 12 months | ||||||
| DAS28-ESR reduction by 1 point | 1.38 | 1.31 to 1.46 | <0.0001 | 1.31 | 1.24 to 1.39 | <0.0001 |
| Pain reduction by 1 point | 1.26 | 1.22 to 1.31 | <0.0001 | 1.13 | 1.09 to 1.17 | <0.0001 |
| Increase in physical capacity by 10 points | 1.22 | 1.17 to 1.29 | <0.0001 | 1.11 | 1.05 to 1.17 | 0.0004 |
| Fatigue reduction by 1 point | 1.02 | 0.98 to 1.05 | 0.3601 | 1.04 | 1.00 to 1.08 | 0.0303 |
| Sleeping disorder reduction by 1 point | 1.02 | 0.99 to 1.05 | 0.3188 | 1.03 | 1.00 to 1.06 | 0.0632 |
| Glucocorticoids 5 to <10 mg/day, ref. <5 mg | 0.81 | 0.71 to 0.92 | 0.0019 | 0.86 | 0.74 to 1.00 | 0.0439 |
| Glucocorticoids 10 to <15 mg/day, ref. <5 mg | 0.46 | 0.34 to 0.62 | <0.0001 | 0.50 | 0.37 to 0.67 | <0.0001 |
| Glucocorticoids ≥15 mg/day, ref. <5 mg | 0.24 | 0.16 to 0.35 | <0.0001 | 0.46 | 0.30 to 0.70 | 0.0004 |
| ≥1 change of therapy after enrolment | 0.63 | 0.55 to 0.73 | <0.0001 | 0.65 | 0.55 to 0.76 | <0.0001 |
| b/tsDMARD therapy | 1.14 | 0.98 to 1.34 | 0.0982 | 1.18 | 1.00 to 1.39 | 0.0504 |
Effects statistically significant at level α=0.05 are marked in bold.
bDMARD, biological disease-modifying antirheumatic drug; BMI, body mass index; DAS28-ESR, Disease Activity Score in 28 joints-erythrocyte sedimentation rate; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.